355 related articles for article (PubMed ID: 19200708)
1. Should individual PI3 kinase isoforms be targeted in cancer?
Jia S; Roberts TM; Zhao JJ
Curr Opin Cell Biol; 2009 Apr; 21(2):199-208. PubMed ID: 19200708
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
Jiang X; Chen S; Asara JM; Balk SP
J Biol Chem; 2010 May; 285(20):14980-14989. PubMed ID: 20231295
[TBL] [Abstract][Full Text] [Related]
3. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
4. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
5. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
6. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
7. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
9. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
10. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
11. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
13. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
Iida M; Harari PM; Wheeler DL; Toulany M
Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
Yip SC; El-Sibai M; Hill KM; Wu H; Fu Z; Condeelis JS; Backer JM
Cell Motil Cytoskeleton; 2004 Nov; 59(3):180-8. PubMed ID: 15468162
[TBL] [Abstract][Full Text] [Related]
15. Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Doepfner KT; Boller D; De Laurentiis A; Guerreiro AS; Marinov M; Arcaro A
Recent Pat DNA Gene Seq; 2007; 1(1):9-23. PubMed ID: 19075915
[TBL] [Abstract][Full Text] [Related]
16. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
Mao N; Zhang Z; Lee YS; Choi D; Rivera AA; Li D; Lee C; Haywood S; Chen X; Chang Q; Xu G; Chen HA; de Stanchina E; Sawyers C; Rosen N; Hsieh AC; Chen Y; Carver BS
Nat Commun; 2021 Aug; 12(1):5053. PubMed ID: 34417459
[TBL] [Abstract][Full Text] [Related]
17. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease.
Rathinaswamy MK; Burke JE
Adv Biol Regul; 2020 Jan; 75():100657. PubMed ID: 31611073
[TBL] [Abstract][Full Text] [Related]
18. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase.
Marqués M; Kumar A; Cortés I; Gonzalez-García A; Hernández C; Moreno-Ortiz MC; Carrera AC
Mol Cell Biol; 2008 Apr; 28(8):2803-14. PubMed ID: 18285463
[TBL] [Abstract][Full Text] [Related]
19. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
20. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
